Literature DB >> 23499736

CEACAM1 regulates Fas-mediated apoptosis in Jurkat T-cells via its interaction with β-catenin.

Yun Li1, John E Shively.   

Abstract

CEACAM1 (Carcinoembryonic Antigen Cell Adhesion molecule 1), an activation induced cell surface marker of T-cells, modulates the T-cell immune response by inhibition of the T-cell and IL-2 receptors. Since T-cells undergo activation induced cell death via Fas activation, it was of interest to determine if this pathway was also affected by CEACAM1. Previously, we identified a novel biochemical interaction between CEACAM1 and the armadillo repeats of β-catenin in Jurkat cells, in which two critical residues, H469 and K470 of the cytoplasmic domain of CEACAM1-4L played an essential role; while in other studies, β-catenin was shown to regulate Fas-mediated apoptosis in Jurkat cells. CEACAM1 expression in Jurkat cells leads to the re-distribution of β-catenin to the actin cytoskeleton as well as inhibition of β-catenin tyrosine phosphorylation and its degradation after Fas stimulation. As a result, Fas-mediated apoptosis in these cells was inhibited. The K470A mutation of CEACAM1 partially rescued the inhibitory effect, in agreement with the prediction that a CEACAM1-β-catenin interaction pathway is involved. Although CEACAM1 has two ITIMs, they were not tyrosine-phosphorylated upon Fas ligation, indicating an ITIM independent mechanism; however, mutation of the critical residue S508, located between the ITIMs, to aspartic acid and a prerequisite for ITIM activation, abrogates the inhibitory activity of CEACAM1 to Fas-mediated apoptosis. Since Fas-mediated apoptosis is a major form of activation-induced cell death, our finding supports the idea that CEACAM1 is a general inhibitory molecule for T-cell activation utilizing a variety of pathways.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23499736      PMCID: PMC3765085          DOI: 10.1016/j.yexcr.2013.02.020

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  26 in total

Review 1.  CEACAM1: contact-dependent control of immunity.

Authors:  Scott D Gray-Owen; Richard S Blumberg
Journal:  Nat Rev Immunol       Date:  2006-06       Impact factor: 53.106

Review 2.  Apoptosis by death factor.

Authors:  S Nagata
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

Review 3.  The role of beta-catenin in cell adhesion, signal transduction, and cancer.

Authors:  L C Bullions; A J Levine
Journal:  Curr Opin Oncol       Date:  1998-01       Impact factor: 3.645

4.  Mutation analysis of the short cytoplasmic domain of the cell-cell adhesion molecule CEACAM1 identifies residues that orchestrate actin binding and lumen formation.

Authors:  Charng-Jui Chen; Julia Kirshner; Mark A Sherman; Weidong Hu; Tung Nguyen; John E Shively
Journal:  J Biol Chem       Date:  2006-12-27       Impact factor: 5.157

5.  Stabilized beta-catenin extends thymocyte survival by up-regulating Bcl-xL.

Authors:  Huimin Xie; Zhaofeng Huang; Maureen S Sadim; Zuoming Sun
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

6.  Camptothecin causes cell cycle perturbations within T-lymphoblastoid cells followed by dose dependent induction of apoptosis.

Authors:  N Johnson; T T Ng; J M Parkin
Journal:  Leuk Res       Date:  1997-10       Impact factor: 3.156

7.  CEACAM1 (CD66a) promotes human monocyte survival via a phosphatidylinositol 3-kinase- and AKT-dependent pathway.

Authors:  Qigui Yu; Edith M C Chow; Henry Wong; Jenny Gu; Ofer Mandelboim; Scott D Gray-Owen; Mario A Ostrowski
Journal:  J Biol Chem       Date:  2006-10-27       Impact factor: 5.157

8.  The cell-cell adhesion molecule carcinoembryonic antigen-related cellular adhesion molecule 1 inhibits IL-2 production and proliferation in human T cells by association with Src homology protein-1 and down-regulates IL-2 receptor.

Authors:  Charng-Jui Chen; John E Shively
Journal:  J Immunol       Date:  2004-03-15       Impact factor: 5.422

9.  CEACAM1 modulates epidermal growth factor receptor--mediated cell proliferation.

Authors:  George A Abou-Rjaily; Sang Jun Lee; Denisa May; Qusai Y Al-Share; Anthony M Deangelis; Randall J Ruch; Michael Neumaier; Holger Kalthoff; Sue-Hwa Lin; Sonia M Najjar
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

10.  High expression of CEACAM6 and CEACAM8 mRNA in acute lymphoblastic leukemias.

Authors:  Adriana Lasa; Elena Serrano; Maite Carricondo; Maria J Carnicer; Salut Brunet; Isabel Badell; Jorge Sierra; Anna Aventín; Josep F Nomdedéu
Journal:  Ann Hematol       Date:  2007-10-02       Impact factor: 3.673

View more
  14 in total

Review 1.  CEACAM1 structure and function in immunity and its therapeutic implications.

Authors:  Walter M Kim; Yu-Hwa Huang; Amit Gandhi; Richard S Blumberg
Journal:  Semin Immunol       Date:  2019-04       Impact factor: 11.130

2.  Induction of Lumen Formation in a Three-dimensional Model of Mammary Morphogenesis by Transcriptional Regulator ID4: ROLE OF CaMK2D IN THE EPIGENETIC REGULATION OF ID4 GENE EXPRESSION.

Authors:  Tung Nguyen; John E Shively
Journal:  J Biol Chem       Date:  2016-06-14       Impact factor: 5.157

3.  Loss of CEACAM1, a Tumor-Associated Factor, Attenuates Post-infarction Cardiac Remodeling by Inhibiting Apoptosis.

Authors:  Yan Wang; Yanmei Chen; Yi Yan; Xinzhong Li; Guojun Chen; Nvqin He; Shuxin Shen; Gangbin Chen; Chuanxi Zhang; Wangjun Liao; Yulin Liao; Jianping Bin
Journal:  Sci Rep       Date:  2016-02-25       Impact factor: 4.379

4.  Abnormal expression of circulating and tumor-infiltrating carcinoembryonic antigen-related cell adhesion molecule 1 in patients with glioma.

Authors:  Jinhu Li; Xiaodong Liu; Yijun Duan; Hongqin Wang; Wen Su; Yazhou Wang; Guotao Zhuang; Yimin Fan
Journal:  Oncol Lett       Date:  2018-01-12       Impact factor: 2.967

Review 5.  CEACAM1 as a multi-purpose target for cancer immunotherapy.

Authors:  Matthew Dankner; Scott D Gray-Owen; Yu-Hwa Huang; Richard S Blumberg; Nicole Beauchemin
Journal:  Oncoimmunology       Date:  2017-05-16       Impact factor: 8.110

Review 6.  Not All Immune Checkpoints Are Created Equal.

Authors:  Annika De Sousa Linhares; Judith Leitner; Katharina Grabmeier-Pfistershammer; Peter Steinberger
Journal:  Front Immunol       Date:  2018-08-31       Impact factor: 7.561

Review 7.  CEACAM1 in Liver Injury, Metabolic and Immune Regulation.

Authors:  Andrea Kristina Horst; Sonia M Najjar; Christoph Wagener; Gisa Tiegs
Journal:  Int J Mol Sci       Date:  2018-10-11       Impact factor: 5.923

8.  Antioxidative CXXC Peptide Motif From Mesencephalic Astrocyte-Derived Neurotrophic Factor Antagonizes Programmed Cell Death.

Authors:  Valentina Božok; Li-Ying Yu; Jaan Palgi; Urmas Arumäe
Journal:  Front Cell Dev Biol       Date:  2018-09-04

9.  CEACAM1 promotes melanoma cell growth through Sox-2.

Authors:  Rona Ortenberg; Gilli Galore-Haskel; Ilanit Greenberg; Bella Zamlin; Sivan Sapoznik; Eyal Greenberg; Iris Barshack; Camila Avivi; Yulia Feiler; Israel Zan-Bar; Michal J Besser; Ester Azizi; Friedman Eitan; Jacob Schachter; Gal Markel
Journal:  Neoplasia       Date:  2014-06-13       Impact factor: 5.715

10.  CEACAM1 controls the EMT switch in murine mammary carcinoma in vitro and in vivo.

Authors:  Florian Wegwitz; Eva Lenfert; Daniela Gerstel; Lena von Ehrenstein; Julia Einhoff; Geske Schmidt; Matthew Logsdon; Johanna Brandner; Gisa Tiegs; Nicole Beauchemin; Christoph Wagener; Wolfgang Deppert; Andrea Kristina Horst
Journal:  Oncotarget       Date:  2016-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.